(204) Non-Inflammatory mRNA-LNP Formulation for the Treatment of Type 1 Diabetes
Introduction: Type 1 Diabetes (T1D) is an autoimmune disease that affects about 2 million Americans1. Our group has developed an mRNA-LNP including cationic phospholipids to physiochemically target the pancreas2. However, cationic lipids may exacerbate pre-existing inflammation in autoimmune diseases, counterproductive to therapeutic goals3. Here, we describe a new mRNA-LNP formulation that does not increase inflammation in non-obese diabetic mice (NOD), a mouse model of T1D, that retains pancreatic tropism. Its lack of adjuvant activity makes it a strong candidate for therapeutic applications in T1D.
Learning Objectives:
Understand the role of LNP composition in exacerbating inflammation.
Demonstrate how mRNA-LNPs can be engineered for pancreatic delivery without increasing inflammation.
